I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study - FiercePharma 26-Jun-2020

I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study - FiercePharma

Cancer patients at Memorial Sloan Kettering who developed COVID-19 faced a higher risk of poor outcomes if they had been treated with checkpoint inhibitors such as Merck's Keytruda, according to a new study.